Surgery Partners, Inc.

SGRYNASDAQHealthcare● Active

$13.86

+$0.15(+1.09%)

Market Cap$1.8B

P/E Ratio—

52W High$24.1

52W Low$11.41

Avg Volume1.5M

Open$13.83

Beta1.95

Free Cash Flow Financials Revenue

Surgery Partners, Inc. (SGRY) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SGRY · free cash flow · updated Jun 8, 2026

Core FCF metrics

SGRY · FCF · TTM · margin & CAGR

Free cash flow was $195.6M for FY2025 (fiscal year ending 2025-12-31), down 6.7% year-over-year The FCF margin was 5.9%. Five-year CAGR stands at -0.8%.

FY2025 Free Cash Flow$195.6M▼ -6.7% YoY

Trailing 12M (TTM)$208.0Mtrailing 4 quarters sum

FCF Margin5.9%$195.6M ÷ revenue

3-Year CAGR+35.7%FY2022 → FY2025

5-Year CAGR-0.8%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SGRY · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$274.3M(79M)$195.6M▼ 6.7%5.9%

FY2024$300.1M(90M)$209.7M▲ +2.3%6.7%

FY2023$293.8M(89M)$205.0M▲ +162.1%7.5%

FY2022$158.8M(81M)$78.2M▲ +165.1%3.1%

FY2021$87.1M(58M)$29.5M▼ 85.5%1.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SGRY · P/FCF · FCF yield · FCF per share

Surgery Partners, Inc. (SGRY) trades at a FCF yield of 11.60% and a price-to-free-cash-flow ratio of 8.5x. FCF per share stands at $1.64, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

11.60%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.64

TTM FCF ÷ Shares Outstanding

Price / FCF

x8.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x27.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

SGRY · cash flow statement · operating / investing / financing

For FY2025, Surgery Partners, Inc. generated $274.3M in operating cash flow and spent 79M in capital expenditures, yielding $195.6M in free cash flow.

Operating Activities

+$274.3M

Cash from core business operations

2025-12-31

Investing Activities

−$246.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$57.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($274.3M) − |CapEx| (79M) = FCF ($195.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SGRY vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Surgery Partners, Inc.YOU

SGRY

$195.6M-6.7%5.9%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Surgery Partners, Inc. (SGRY) reported free cash flow of $195.6M for FY2025 (fiscal year ending 2025-12-31), down 6.7% year-over-year. The FCF margin was 5.9%.

Based on available data, Surgery Partners, Inc. has maintained positive free cash flow for at least 14 fiscal year(s). FCF peaked at $209.7M in FY2024. The 5-year CAGR stands at -0.8%.

Surgery Partners, Inc.'s FCF yield is 11.60% and price-to-FCF ratio is 8.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SGRY free cash flow · 8 questions

Surgery Partners, Inc. free cash flow was $195.6M for FY2025, down 6.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $208.0M.

SGRY free cash flowSGRY FCFSGRY FCF 2025SGRY free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Surgery Partners, Inc. · Surgery Partners, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026